Rafferty Asset Management’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Rafferty Asset Management’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-3,424	Closed	-$349K	–	1112
2023 Q2	$349K	Buy	+3,424	New	+$324K	﹤0.01%	1028
2022 Q1	–	Sell	-11,450	Closed	-$302K	–	1344
2021 Q4	$302K	Buy	11,450 +4,633	+68%	+$359K	﹤0.01%	1151
2021 Q3	$686K	Buy	6,817 +4,215	+162%	+$494K	﹤0.01%	970
2021 Q2	$368K	Buy	2,602 +94	+4%	+$10.6K	﹤0.01%	1133
2021 Q1	$250K	Sell	2,508 -882	-26%	-$103K	﹤0.01%	1114
2020 Q4	$419K	Sell	3,390 -352	-9%	-$46.3K	﹤0.01%	722
2020 Q3	$365K	Buy	3,742 +1,911	+104%	+$239K	﹤0.01%	762
2020 Q2	$286K	Buy	+1,831	New	+$278K	﹤0.01%	841
2020 Q1	–	Sell	-1,970	Closed	-$403K	–	845
2019 Q4	$403K	Sell	1,970 -1,272	-39%	-$232K	0.01%	725
2019 Q3	$260K	Buy	+3,242	New	+$275K	﹤0.01%	760

Other funds holding RETA

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Rafferty Asset Management's RETA Position: Q3 2023 in Review

Rafferty Asset Management sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 3,424 shares — an estimated $349K sold.

Rafferty Asset Management first reported a position in RETA in Q3 2019 and held it in 10 quarters. The position peaked at $686K in Q3 2021. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.

Rafferty Asset Management reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
Rafferty Asset Management sold 3,424 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $349K.
Rafferty Asset Management first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q3 2019 and held it in 10 quarters.
Rafferty Asset Management's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $686K in Q3 2021.
2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.

Based on Rafferty Asset Management's 13F filing for Q3 2023, filed 13 Nov 2023.